论文部分内容阅读
目的观察干扰素联合氨溴索治疗小儿支气管肺炎的治疗效果。方法选取2014年1月-2016年12月收治的小儿支气管肺炎患儿200例,随机分为2组,治疗组给予干扰素联合氨溴索雾化吸入治疗,对照组给予氨溴索雾化吸入治疗,比较2组临床症状改善时间、临床疗效及不良反应。结果治疗组退热、咳嗽消失、气促改善及肺部啰音消失时间均短于对照组,差异均有统计学意义(P<0.05)。治疗组总有效率为96.0%高于对照组的86.0%,差异有统计学意义(χ~2=6.11,P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论干扰素联合氨溴索雾化吸入治疗小儿支气管肺炎疗效显著,且安全性好,值得临床推广应用。
Objective To observe the therapeutic effect of interferon combined with ambroxol on bronchial pneumonia in children. Methods A total of 200 children with bronchial pneumonia admitted from January 2014 to December 2016 were randomly divided into two groups. The treatment group received inhalation of interferon combined with ambroxol and the control group received ambroxol inhalation Treatment, compared two groups to improve the clinical symptoms, clinical efficacy and adverse reactions. Results The treatment group fever, cough disappear, improve shortness of breath and pulmonary rales disappeared shorter than the control group, the difference was statistically significant (P <0.05). The total effective rate in the treatment group was 96.0%, which was significantly higher than that in the control group (χ ~ 2 = 6.11, P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Interferon combined with ambroxol inhalation in children with bronchopneumonia is effective and safe. It is worthy of clinical application.